Table 1.
Chitosan nanoparticles designed for the treatment of HCC and liver-targeting: the therapeutic/theranostic effect and cell cultures used in the study are reported for each reference.
| Carrier | Payload | Effect | Cell Culture | Reference |
|---|---|---|---|---|
| Chitosan | - | anti-cancer | BEL7402; H22 | [52,53] |
| Chitosan | - | anti-cancer | BEL7402 | [54,55] |
| Chitosan | - | anti-cancer inhibition of lipid peroxidation | - | [56] |
| Chitosan | - | anti-cancer | HepG2 | [57] |
| Chitosan | - | anti-cancer | - | [58] |
| Chitosan | 125I-labeled 5-Iodo-2′deoxyuridine | anti-cancer | HepG2 | [59] |
| Chitosan | hydroxycamptothecin | anti-cancer | HepG2 | [60] |
| Chitosan | CD147 antibody | anti-cancer tumor necrosis | HepG2 | [61] |
| Chitosan | doxorubicin | anti-cancer | HepG2 | [62] |
| Chitosan-PLGA | epirubicin | anti-cancer anti-angiogenic | - | [63] |
| Chitosan-PLA | piceatannol | anti-cancer anti-oxidant | HepG2 | [64] |
| Chitosan iron oxide | SPIONs | magnetic resonance imaging(MRI) | - | [65] |